Fertility and fertility preservation techniques for breast cancer patients

Size: px
Start display at page:

Download "Fertility and fertility preservation techniques for breast cancer patients"

Transcription

1 Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society OPINION Fertility and fertility preservation techniques for breast cancer patients Fouzia Memon, M.B.B.S. Research Fellow, Newcastle upon Tyne NHS Foundation Trust, UK. ABSTRACT. Breast cancer is not rare in younger women. There has been remarkable improvement in the survival rate due to progress in cancer treatment. Those treatments often cause premature ovarian failure due to massive destruction of the ovarian reserve. Early loss of ovarian function not only puts the patient at risk for menopause-related complications at a very young age but is also associated with loss of fertility. The purpose of this paper is to review the incidence of gonadal toxicity associated with adjuvant chemotherapy, fertility concerns, and the options to preserve fertility in young breast cancer survivors. Key words: Breast cancer, premenopausal, reproduction, fertility preservation. INTRODUCTION Breast cancer is the most common female malignancy. There are 2.2 million breast cancer survivors and approximately 25-30% of newly diagnosed breast cancer patients each year are <50 year of age. Sonmezer et al (2006) and Ghafoor et al (2003) found that the incidence of breast cancer has increased by 0.5% per year over the past decade, whereas the death rate has decreased by 1.4% per year during the same period (1, 2). The estimated incidence is less than 0.1 per 100,000 women below the age of 20 years, increasing to 1.4 for women years, 8.1 for women years and 24.8 for women year old (3). The decline in mortality is more remarkable in women age <50 year (4). With the lower mortality and longer survival rate resulting from adjuvant therapy, chemotherapy or endocrine therapy may be recommended to women <50 year of age, depending on the stage, prognostic factors, and hormone sensitivity of the tumor. The use of adjuvant cytotoxic chemotherapy for the treatment of breast cancer can induce ovarian failure and infertility, while the use of adjuvant hormonal therapy is a contraindication to conception during therapy. Further, women in this millennium have been delaying initiation of childbearing to later in life, hence the preservation of fertility in female patients diagnosed with cancer has recently been an area of intensive investigation. This article reviews the literature, discusses the pathophysiology and effect of breast cancer treatment on fertility, chances of spontaneous pregnancy and summarizes available fertility preservation options and discusses recently published data concerning experimental methods. The problem: gonadal damage induced by chemotherapy Damage to the gonads by chemotherapy depends on the patient s age at the time of treatment, total dose and nature of chemotherapy Vol. 12, No. 3, 2007 Memon Fertility and breast cancer 153

2 delivered. The exact mechanism of ovarian damage is not fully understood, but in-vitro studies suggest apoptotic changes in the granulosa cells that result in follicular damage (5). Chemotherapeutic drugs used in various combinations for the treatment of breast cancer, such as three-drug combination of cyclophosphamide and fluorouracil with either methotrexate (CMF) or an anthracyclin (CAF, FAC) (6). The addition of Paclitaxel (taxanes) in addition to cyclophosphamide have been shown to possibly increase gonadotoxicity (7), Although earlier on Stone in 2000 (8), Swain in 2005 (9) and Ball in 2001 (10) found that adjuvant chemotherapy in women (<45) with or without taxanes resulted in a slightly lower incidence of amenorrhea in young women. The alkylating agents such as cyclophosphamide, which can damage resting cells, is more toxic to the ovaries than cell cycle specific agents, such as methotrexate and fluorouracil, whose major effect is on ovarian follicle growth and maturation (11,12). Ovarian biopsies performed in women undergoing treatment with cyclophosphamide showed stromal fibrosis, marked reductions in the number of oocytes, and the lack of follicular maturation (13). Since the cell cycle specific agents damage growing follicles therefore sex steroid production is interrupted, which may lead to disturbance of the hypothalamic-pituitaryovarian axis, with eventual irregular menses, amenorrhea, and menopausal symptoms. In the absence of ovarian production of estradiol, feedback inhibition on the pituitary is lost and follicle stimulating hormone (FSH) levels rise to menopausal levels. Follicle stimulating hormone levels are frequently used to assess ovarian failure and ovarian reserve in women who have abnormal menses or amenorrhea after receiving chemotherapy. Most of the data pertaining to the likelihood of having amenorrhea with adjuvant chemotherapy for early breast cancer from women having cyclophosphamide, methotrexate, 5- fluorouracil (CMF) and these results may not be directly comparable to anthracycline-based chemotherapy regimens. In the MD Andersen hospital and tumor institute series, no patient Less than 30 years of age treated with a doxorubicincontaining regimen stopped menstruating compared with 33% of patients aged years and 96% of those aged years (14). Tamoxifen, a selective estrogen modulator with antiestrogenic actions on breast tissue, is an important part of the adjuvant therapy for earlystage, hormone-sensitive breast cancer. In addition to symptoms associated with the hormonal changes of induced menopause due to antiestrogenic effects, endocrine therapy is also associated with a variety of other symptoms, that include vasomotor symptoms, vaginal complaints (dryness, itching, discharge), amenorrhea, insomnia, and mood disturbances (15). Adjuvant therapy with tamoxifen do not cause permanent amenorrhea, but tamoxifen treatment can last up to 5 years, during which pregnancy is contraindicated. (16). Spontaneous pregnancy after chemotherapy Overall, at least half of women under 35 years of age resume menses at some time after completion of chemotherapy (17, 18). On the flip side, resumption of menstruation after chemotherapy does not mean that fertility has been preserved. Studies are not available which assess actual fertility since they require longer follow-up, determination of premorbid fertility, and determination of the percentage of patients who attempt conception. In one study evaluating 119 women aged 35 years or younger who had been treated with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) there were 33 pregnancies among 25 women who either continued or resumed menstruating (21%). The median age of those who became pregnant were 28 years (range 22-33), and the median interval between the last chemotherapy treatment and pregnancy was 12 months (Range 0-87). The overall reproductive potential of this group of women could not be assessed, since no attempt was made to determine what percentage of the menstruating women attempted conception or used contraception. Of the 33 pregnancies there were 10 elective abortions, two spontaneous abortions, 19 full term pregnancies and two women were pregnant at the time of the report. There were no preterm deliveries and no fetal abnormalities among the 19 live offspring (18). 154 Memon Fertility and breast cancer MEFSJ

3 Fertility preservation strategies There is a recognized need to discuss fertility and options to preserve fertility before adjuvant chemotherapy for young women with breast cancer. Surveys of cancer patients reveal a very strong desire to be informed of available options for fertility preservation and future reproduction (19). The desire for biologic motherhood and a genetically related child is an important issue for many cancer survivors. In breast cancer, many clinicians recommend that women should wait to consider pregnancy for 2-3 years after completion of cancer treatment because of the highest risk for early recurrence in these years. The decision will depend on the patient s medical status and prognosis, her partner status, her age, whether reproduction can safely occur for patient and reproductive options available to them. The management of the gonadal toxicity of adjuvant chemotherapy for breast cancer is complex. It is important to consider the possibility of preventing ovarian toxicity and the therapeutic options available if infertility occurs. Potential options for fertility preservation include cryopreservation of mature oocytes, embryo cryopreservation following in-vitro fertilization (IVF) and ovarian tissue cryopreservation (20, 21). To date the most effective approach is embryo cryopreservation, because the human embryo is the most resistant to damage caused by cryopreservation. This method requires in vitro fertilization and a male partner (22). However, cryopreservation of embryos or mature oocytes is frequently not a feasible option for reasons that include the unknown risk of the hormonal stimulation required for oocyte harvest and the inherent delay in starting chemotherapy. Cryopreservation of oocytes is not a clear option because of poor outcomes related to cryodamage of the oocyte in the process, arrested embryonic development, and increased chromosomal abnormalities in fertilized cryo-preserved oocytes. The exceptionally low pregnancy rate does not justify the use of this option for routine clinical practice. The overall published live birth rate per cryopreserved oocyte is seldom-greater than1% to 5 % (23) which is much lower than with IVF using fresh oocytes. It has been postulated that suppression of germ cell stimulation may lead to the protection of oocytes and ovarian follicles from toxic effects of chemotherapy. Although preliminary data about using gonadotropins releasing hormone agonists concomitantly with the chemotherapy suggest that ovarian protection may be possible (24), there have been contradictory results regarding their use also (25). Many clinical trials using oral contraceptives or GnRH antagonists to suppress ovarian function during chemotherapy have had disappointing results (26). One possible reason for the lack of protection by GnRH analogue may be that the need for timely treatment of the cancer does not allow for the complete suppression of the ovarian germinal epithelium. The use of oral contraceptives prior to, or during adjuvant chemotherapy for breast cancer may stimulate growth of occult micro metastases. Other considerations include potentially increasing the risk of venous thrombosis that is seen in women receiving adjuvant chemotherapy for breast cancer and blockage of pituitary releasing factors that may result in reflex stimulation of ovarian oestrogen production (27). There has been recent interest in banking ovarian tissue (22), rather than oocytes alone, with auto grafting of the stored tissue following chemotherapy. This technique, too, requires further investigation before it can be recommended to patients. It is anticipated that ovarian tissue will be thawed and implanted after cancer treatment as an auto graft or to a heterotrophic site or that technique for maturing oocytes in vitro will be developed in the future. With ovulation and creation of a human embryo from ovarian tissue transplanted to the arm and live birth from a antilogous ovarian transplant already reported (22, 28), further successes in the future are likely. In July 2005, a case report was published of a successful pregnancy and birth in a woman with a history of non- Hodgkin s lymphoma using transplantation cryopreserved ovarian tissue and in-vitro fertilization (29) although according to the authors they cannot rule out that the egg came from the native ovary rather than transplanted Vol. 12, No. 3, 2007 Memon Fertility and breast cancer 155

4 tissue, however the patient s 24 month history of amenorrhea after chemotherapy and hormonal profile argue that the fertilization was related to the transplanted tissue. For women who are infertile following chemotherapy, reproductive choices remain limited. In a step forward researchers from United Kingdom have successfully generated primitive sperm cells from human bone marrow derived stem cells (30). Although the use of such gamete is currently illegal in United Kingdom; such work offers the hope that derived oocytes and sperms may yet be possible. Finally for breast cancer survivors who rendered menopausal or with severely damaged ovaries following treatment adoption or childlessness may still be considered. There remains however the possibility of egg donation, which through the IVF process can offer excellent chances of a successful pregnancy. CONCLUSION The diagnosis of breast cancer can be devastating to young patients who desire future fertility. This review identifies the physical damage the breast cancer treatment has on young breast cancer survivors. Breast cancer chemotherapy especially alkylating agents cause destruction of primordial follicles resulting in reversible amenorrhea, irregular menses, or irreversible amenorrhea (ovarian failuremenopause). Younger women have a lower risk for amenorrhea with chemotherapy because of good ovarian reserve, although the gonadal toxicity may result in an earlier than expected menopause. The standard therapy for breast cancer treatment often result in sterility either temporary or permanent. The chances of spontaneous pregnancy still exist after cancer treatment. although a bit reduced. Currently there is uncertainty over the most effective and appropriate strategies for preserving and/or restoring an individual s fertility. There are several considerations of fertility preservation for women who are interested in having biological child after a diagnosis of breast cancer. The decisions of whether to resort to fertility preservation and which method to use depend on a number of factors including patient s age, the type of adjuvant therapy, and the time available before chemotherapy and the length of delay to childbearing post chemotherapy. The most recognized option for fertility preservation at present is embryo freezing. To conclude, knowledge of pathways by which chemotherapy causes injury to reproductive function may help in the development of treatment strategies for reproductive organ protection as well as fertility preservation techniques. The improvements of these techniques as well as better characterization of their success rates and risks await further investigations. Summary box 1 Recognized methods of fertility preservation *Embryo cryopreservation following in-vitro fertilization *Oocyte cryopreservation Experimental methods of fertility preservation *Ovarian tissue banking *Hormonal manipulation e.g. GnRH analogue, GnRH antagonists or oral contraceptive pills. Future strategies *Gamete formation from human stem cells 156 Memon Fertility and breast cancer MEFSJ

5 REFERENCES 1. Sonmezer Murat, Kutluk Oktay. Fertility preservation in young women undergoing breast cancer therapy. The Oncologist 2006, Vol.11, No. 5, , May, 1634/theoncologist Ghafoor A, Jemal A, Ward E. Trends in breast cancer by race and Ethnicity. CA Cancer J Clin 2003; 53, Shannon C, and Smith IE. Breast cancer in adolescents and young women. European Journal of cancer 2003; 39:18, Early breast cancer trialists collaborative group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: Meirow D, Lewis H, Nugent D et al. Sub clinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999; 14: Knobf M, Tish. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist 2006; 11 (2): Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, and Cameron DA. The effects of chemotherapy and long-term gonatrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006; 21 (10): Stone ER, Slack RS, Novielli A. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adriamycin and cytoxan followed by Taxol (AC+T) in early stage breast cancer. Breast Cancer Res Treat 2000; 64:61a. 9. Swain SM, Land SR, Sundry R. Amenorrhea in premenopausal women on the doxorubicin and cyclophosphamide (C)-docetaxol (T) arm of NSABP-30: preliminary results. Proc Am Soc Clin Oncol 2005; 16s: 537a. 10. Ball J, Fox K. Age-associated incidence of chemotherapy-related amenorrhea (CRA) following adjuvant doxorubicin, cyclophosphamide and paclitaxel (AC/TAXOL) in early stage breast cancer. Proc Am Soc Clin Oncol 2001; 20:16a. 11. Viviani S, Santtoro A, Ragni G. Gonadal toxicity after combination chemotherapy for Hodgkin s disease: comparative results from MOPP and ABVD. Eur J Clin Oncol 1985; Warne GL, Fairley KF, Hobbs JB. Cyclophosphamideinduced ovarian failure. New Engl J Med 1973; Hortobagyi GN, Buzdar AU, Marcus CE, and Smith TL. Immediate and long term of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D.Anderson Hospital and tumor institute. NCL Monogr 1986; 1, Hensley L, Martee and Bonnie S.Reichman. Fertility and pregnancy after Adjuvant chemotherapy for breast cancer. Critical reviews in oncology/haematology 1998, Volume 28, 2, Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr 2001;(30): Gradishar WJ, and Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 1989; Forbes JF. Long-term effects of adjuvant chemotherapy in breast cancer. Acta Oncol 1992; Sutton R, Buzdar AU, and Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 65 (1990). 19. Mor V, Malin M, and Allen S. Age differences in psychological problems encountered by breast cancer patients. Journal of the National Cancer Institute Monographs 1994; 16: Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation. Hum Reprod 2004, 19, Stachecki JJ and Cohen J. An overview of oocyte cryopreservation, Reprod Biomed Online 2004; 9; Fox K, Scialia J, Moore H. Preventing chemotherapyrelated amenorrhea using leuprolide during adjuvant chemotherapy for early stage breast cancer. Proc Am Soc Clin Oncol 2003, 22:13a. 23. Letterie GS. Anovulation in the prevention of cytotoxicinduced follicular attrition and ovarian failure. Hum Reprod 2004; 19: Donnez J, Dolmans MM, Demylle D, Jadoul P. Live birth after orthographic transplantation of cry preserved ovarian tissue. Lancet 2004, Blumenfeld Z, Avivi I, Linn S. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: Nayernia Karim. Bone stem cells turned into primitive sperm cells-sex-13 April New Scientist. Vol. 12, No. 3, 2007 Memon Fertility and breast cancer 157

03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline

03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March

More information

FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013

FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013 FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013 SPECIAL THANKS TO DR. MINDY CHRISTIANSON INTRODUCTION About 6-7% of breast cancers are diagnosed

More information

10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.

10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States. The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence

More information

Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center

Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Cancer and Fertility Ashley Munchel, MD Assistant Professor of Pediatrics University of Maryland Medical Center Trends in Pediatric Cancer Incidence Rates by Site, Ages Birth to 19 Years, 1975 to 2010.

More information

Melanoma-What Every Woman Need to Know about Fertility and Pregnancy

Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Melanoma-What Every Woman Need to Know about Fertility and Pregnancy Women diagnosed with melanoma may require counseling for fertility preservation, fertility treatment and safety of pregnancy after treatment.

More information

Gynecologic Considerations in Women with FA

Gynecologic Considerations in Women with FA Gynecologic Considerations in Women with FA RAHEL GHEBRE, M.D., MPH University of Minnesota Medical School Objectives Recommendation for Gynecologic Care FA girls starting at age 16 should establish a

More information

FERTILITY PRESERVATION. Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida

FERTILITY PRESERVATION. Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida FERTILITY PRESERVATION Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida 1 2 3 4 Oocyte Cryopreservation Experimental option Offer to single cancer

More information

Optimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE

Optimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers

More information

La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana

La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma Olivia Pagani Centro di Senologia dellasvizzera Italiana Centro di Senologia della Svizzera Italiana Pregnancy rate after

More information

Obstetrics, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium

Obstetrics, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium The Oncologist Prevention Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin s Disease ISABELLE DEMEESTERE, a,b PHILIPPE

More information

L ess than 20% of women with breast cancer are premenopausal, ONLINE EXCLUSIVE

L ess than 20% of women with breast cancer are premenopausal, ONLINE EXCLUSIVE ONLINE EXCLUSIVE This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase reprints or request permission to reproduce, e-mail reprints@ons.org. Downloaded

More information

Chapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation

Chapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation Chapter 17 Oncofertility Consortium Consensus Statement: Guidelines for Ovarian Tissue Cryopreservation Leilah E. Backhus, MD, MS, Laxmi A. Kondapalli, MD, MS, R. Jeffrey Chang, MD, Christos Coutifaris,

More information

Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study

Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study Analysis Concept Proposal 1. Study Title Updated Analysis of Non-Surgical Premature Menopause in the Childhood Cancer Survivor Study 2. Working Group and Investigators CCSS Working Group: Chronic Disease

More information

Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers

Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Andrea Reh, M.D., Ozgur Oktem, M.D., and Kutluk Oktay, M.D.

More information

Disturbances of female reproductive system in survivors of childhood cancer

Disturbances of female reproductive system in survivors of childhood cancer Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the

More information

Chapter 4. Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007

Chapter 4. Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 Chapter 4 Managing Fertility in Childhood Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication of this article is available at www.springerlink.com

More information

CHEMOTHERAPY. Chemo, Ctx, Ctx. A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female

CHEMOTHERAPY. Chemo, Ctx, Ctx. A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female CHEMOTHERAPY Chemo, Ctx, Ctx A category of cancer treatment that uses one or more anti-cancer drugs. Risk factor Male & Female About Chemotherapy Chemotherapy is a category of cancer treatment that uses

More information

References 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa

References 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, (1): p Keegan, T.H., et al., Compa 1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): p. 7 30. 2. Keegan, T.H., et al., Comparison of cancer survival trends in the United States of adolescents

More information

Planning for Parenthood After a Cancer Diagnosis

Planning for Parenthood After a Cancer Diagnosis Cancer and Fertility Planning for Parenthood After a Cancer Diagnosis If you or someone you love is facing cancer, preserving fertility may be the last thing on your mind. But if you re a woman of childbearing

More information

REPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS

REPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS REPRODUCTIVE HEALTH IN YOUNG ADULT CANCER SURVIVORS Laxmi A Kondapalli, MD MSCE Colorado Center for Reproductive Medicine Disclosure The speaker has no financial or other conflict of interest Objectives

More information

Should we offer fertility preservation to all patients with severe endometriosis?

Should we offer fertility preservation to all patients with severe endometriosis? Should we offer fertility preservation to all patients with severe endometriosis? Daniel S. Seidman, MD Department of Ob/Gyn, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Endometriosis

More information

LOW RESPONDERS. Poor Ovarian Response, Por

LOW RESPONDERS. Poor Ovarian Response, Por LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients

More information

Fertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital

Fertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Fertility Preservation for Breast Cancer Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Learning Objectives To be able to list and describe processes of ovulation induction

More information

Chemotherapy-Induced Amenorrhea and Fertility in Women Undergoing Adjuvant Treatment for Breast Cancer

Chemotherapy-Induced Amenorrhea and Fertility in Women Undergoing Adjuvant Treatment for Breast Cancer Treatment-related morbidity and long-term sequelae related to chemotherapy-induced amenorrhea are assuming greater importance as the number of breast cancer survivors increases. Nancy Graves. Canoptic

More information

Impact of chemotherapy-induced amenorrhea on the prognosis of early breast cancer patients

Impact of chemotherapy-induced amenorrhea on the prognosis of early breast cancer patients Impact of chemotherapy-induced amenorrhea on the prognosis of early breast cancer patients Hanaa M.Kohel, MD 1 ; Yousri A.Rostom, MD 2 ; Osama H.El-Zaafarany, MD 3 ; Hazem F.Elaakad, MD 4 (1)Medical Research

More information

M. Tish Knobf. Yale School of Nursing, New Haven, Connecticut, USA

M. Tish Knobf. Yale School of Nursing, New Haven, Connecticut, USA This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer The Influence of Endocrine Effects of Adjuvant

More information

Fertility care for women diagnosed with cancer

Fertility care for women diagnosed with cancer Saint Mary s Hospital Department of Reproductive Medicine Information for Patients Fertility care for women diagnosed with cancer Contents Page Overview... 2 Our service... 2 Effects of cancer treatment

More information

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.

Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility

More information

Fertility Preservation. Anne Katz PhD RN FAAN

Fertility Preservation. Anne Katz PhD RN FAAN Fertility Preservation Anne Katz PhD RN FAAN Why is fertility preservation important to YAs after cancer? Normality (Crawshaw & Sloper, 2010) Preference for biologic offspring vs. adoption (Schover 2002)

More information

Fertility and breast cancer

Fertility and breast cancer Review Fertility and breast cancer Joanna Kufel-Grabowska, MD, PhD Greater Poland Cancer Centre in Poznań, Poland Received: 14.07.2016. Accepted: 25.09.2016. ABSTRACT Breast cancer is the most common cancer

More information

Breast cancer & Fertility. Do we provide good information?

Breast cancer & Fertility. Do we provide good information? Breast cancer & Fertility. Do we provide good information? M Fastrez, C Houba 27 4 13 CHU S t Pierre Réseau IRIS University of Brussels We have no conflict of interest to disclose. Summary Introduction:

More information

Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant

Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Ovarian function and pregnancy after Hematopoietic Stem Cell Transplant Factors that influence post transplantation fertility and ovarian function in women Total body irradiation (TBI) Drugs prescribed

More information

Age Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles?

Age Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? Age Related Fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? Age Related fertility Preservation: Should you Consider Multiple Egg Freezing Cycles? All what we really know for sure

More information

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation

More information

Female Health Issues after Treatment for Childhood Cancer

Female Health Issues after Treatment for Childhood Cancer Female Health Issues after Treatment for Childhood Cancer The effects of childhood cancer therapy on female reproductive function depend on many factors, including the girl s age at the time of cancer

More information

T.K. Woodruff et al. (eds.), Oncofertility, Cancer Treatment and Research 156, 3 DOI / _1.

T.K. Woodruff et al. (eds.), Oncofertility, Cancer Treatment and Research 156, 3 DOI / _1. Chapter 1 Reproductive Health After Cancer Clarisa R. Gracia C.R. Gracia (B) Department of Reproductive Endocrinology and Infertility, University of Pennsylvania, Philadelphia, PA, USA e-mail: cgracia@obgyn.upenn.edu

More information

Symptom Management. Fertility and You

Symptom Management. Fertility and You Symptom Management Fertility and You Table of Contents 3 Will cancer impact my ability to have children? 4 How do I talk to my children about preserving their fertility during cancer treatment? 5 What

More information

Reproductive Options for Breast Cancer Patients

Reproductive Options for Breast Cancer Patients 08:36 1 Reproductive Options for Breast Cancer Patients Mr Stuart Lavery Director IVF Hammersmith Consultant Gynaecologist Imperial College London 08:36 2 Reproductive Options for Female Cancer Patients

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Infertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF

Infertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility

More information

Cancer & Fertility: Patient Education Booklet. information suppor t hope

Cancer & Fertility: Patient Education Booklet. information suppor t hope Cancer & Fertility: Patient Education Booklet information suppor t hope 1 table of contents introduction 1 men Fertility Risks 2 Fertility Preservation Options 3 Possible Fertility Outcomes 4 Parenthood

More information

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy. Murat Sonmezer, Kutluk Oktay

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy. Murat Sonmezer, Kutluk Oktay This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Breast Cancer Fertility Preservation in Young Women Undergoing

More information

a nonprofit organization Cancer & Fertility Fast Facts for Ob/Gyns information support hope

a nonprofit organization Cancer & Fertility Fast Facts for Ob/Gyns information support hope a nonprofit organization Cancer & Fertility Fast Facts for Ob/Gyns information support hope table of contents introduction introduction 1 role of the obstetrician-gynecologist cancer screening and diagnosis

More information

Dear doctor, what about a baby? Myths and facts

Dear doctor, what about a baby? Myths and facts Dear doctor, what about a baby? Myths and facts OLIVIA PAGANI BREAST UNIT AND INSTITUTE OF ONCOLOGY OF SOUTHERN SWITZERLAND IBCSG Background About 15% of patients with BC are diagnosed during their reproductive

More information

Cancer Fertility. Fertility Options to Consider Before Treatment Begins & Parenthood Options After Cancer

Cancer Fertility. Fertility Options to Consider Before Treatment Begins & Parenthood Options After Cancer & Cancer Fertility Fertility Options to Consider Before Treatment Begins & Parenthood Options After Cancer If you or someone you care about is faced with a cancer diagnosis, preserving fertility may be

More information

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve

More information

Testosterone Therapy-Male Infertility

Testosterone Therapy-Male Infertility Testosterone Therapy-Male Infertility Testosterone Therapy-Male Infertility Many men are prescribed testosterone for a variety of reasons. Low testosterone levels (Low T) with no symptoms, general symptoms

More information

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen? CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,

More information

Oocyte Freezing and Ovarian Tissue Cryopreservation:

Oocyte Freezing and Ovarian Tissue Cryopreservation: Oocyte Freezing and Ovarian Tissue Cryopreservation: Comparing Results of These Two Methods in One Program Dr. César Díaz García cesar.diaz@ivi.uk IVI London 83, Wimpole St. London, UK London Conflict

More information

The reproductive lifespan

The reproductive lifespan The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary

More information

Review Article Cancer, Fertility Preservation, and Future Pregnancy: AComprehensiveReview

Review Article Cancer, Fertility Preservation, and Future Pregnancy: AComprehensiveReview Obstetrics and Gynecology International Volume 2012, Article ID 953937, 11 pages doi:10.1155/2012/953937 Review Article Cancer, Fertility Preservation, and Future Pregnancy: AComprehensiveReview Michelle

More information

Oncofertility: The Preservation of Fertility Options for Young People with Cancer

Oncofertility: The Preservation of Fertility Options for Young People with Cancer Oncofertility: The Preservation of Fertility Options for Young People with Cancer Teresa K. Woodruff, Ph.D. The Thomas J. Watkins Professor of Obstetrics and Gynecology Northwestern University Feinberg

More information

Onco-fertility. Fertility issues in young women with breast cancer in Japan. National Cancer Center Hospital, Tokyo Chikako Shimizu, MD

Onco-fertility. Fertility issues in young women with breast cancer in Japan. National Cancer Center Hospital, Tokyo Chikako Shimizu, MD Onco-fertility Fertility issues in young women with breast cancer in Japan National Cancer Center Hospital, Tokyo Chikako Shimizu, MD COI disclosure Chikako Shimizu receives contracted research fund from

More information

INTRODUCTION TABLE OF CONTENTS. If you want to become a parent after cancer, we would like to give you the information you need to make that happen.

INTRODUCTION TABLE OF CONTENTS. If you want to become a parent after cancer, we would like to give you the information you need to make that happen. TABLE OF CONTENTS INTRODUCTION INTRODUCTION 1 MEN Fertility Risks 2 Fertility Preservation Options 3 Possible Fertility Outcomes 4 Parenthood After Cancer Options 5 Important Tips for Men 6 WOMEN Fertility

More information

Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002

Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from

More information

Reproductive function in cancer survivors

Reproductive function in cancer survivors Reproductive function in cancer survivors Professor W Hamish Wallace hamish.wallace@nhs.net Symposium 20: Endocrine consequences of childhood cancer treatment Liffey Hall 2, 0905 19 May 2015 CONFLICT OF

More information

SARCOMA/GIST AND FERTILITY

SARCOMA/GIST AND FERTILITY SARCOMA/GIST AND FERTILITY Christine Rousset-Jablonski Medical Gynecologist Léon Bérard Cancer Center, Lyon SPAEN conference, Milan 2018 Fertility/ Pregnancy after cancer A major concern for patients surviving

More information

Clinical Policy Committee

Clinical Policy Committee Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment and investigations are commissioned where: A woman is of reproductive age and has not conceived after one (1) year

More information

OVARIAN FUNCTION AFTER CHILDHOOD CANCER

OVARIAN FUNCTION AFTER CHILDHOOD CANCER OVARIAN FUNCTION AFTER CHILDHOOD CANCER Practicing through Controversy Diane Puccetti MD Leslie Coker Appiah MD NASPAG April 2018 Objectives Review use and limitations of risk stratification. Understand

More information

DRAFT Policy for the Provision of NHS funded Gamete Retrieval and Cryopreservation for the Preservation of Fertility

DRAFT Policy for the Provision of NHS funded Gamete Retrieval and Cryopreservation for the Preservation of Fertility NHS Birmingham and Solihull Clinical Commissioning Group NHS Sandwell and West Birmingham Clinical Commissioning Group DRAFT Policy for the Provision of NHS funded Gamete Retrieval and Cryopreservation

More information

Spontaneous recovery of ovarian function and fertility after cancer treatment

Spontaneous recovery of ovarian function and fertility after cancer treatment Rigshospitalet The Fertility Clinic Copenhagen, Denmark Spontaneous recovery of ovarian function and fertility after cancer treatment Kirsten Tryde Macklon, Ph.D. 5th society of reproductive medicine and

More information

Clinical Policy Committee

Clinical Policy Committee Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility treatments

More information

Key Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines

Key Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES

More information

UTERINE LEIOMYOSARCOMA. About Uterine leiomyosarcoma

UTERINE LEIOMYOSARCOMA. About Uterine leiomyosarcoma UTERINE LEIOMYOSARCOMA Uterine Lms, Ulms Or Just Lms Rare uterine malignant tumour that arises from the smooth muscular part of the uterine wall. Diagnosis Female About Uterine leiomyosarcoma Uterine LMS

More information

Causes of Infertility and Treatment Options

Causes of Infertility and Treatment Options Causes of Infertility and Treatment Options Dr Mrs.Kiran D. Sekhar Former vice President-FOGSI Former Chairperson- Genetics and Foetal medicine-fogsi Founder and Medical Director-Kiran Infertility centre

More information

Principles of Ovarian Stimulation

Principles of Ovarian Stimulation Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle

More information

9.4 Regulating the Reproductive System

9.4 Regulating the Reproductive System 9.4 Regulating the Reproductive System The Reproductive System to unite a single reproductive cell from a female with a single reproductive cell from a male Both male and female reproductive systems include

More information

Infertility treatment

Infertility treatment In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation

More information

American Society of Clinical Oncology June , New Orleans

American Society of Clinical Oncology June , New Orleans American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference

More information

Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often

More information

Endocrine Late Effects in Survivors of Pediatric SCT

Endocrine Late Effects in Survivors of Pediatric SCT Endocrine Late Effects in Survivors of Pediatric SCT Daphna Hutt Pediatric Hem-Onc & BMT Sheba Medical Center, Israel #EBMT2015 www.ebmt.org Stiller CA (2007). Childhood Cancer In Britain. Oxford University

More information

Pediatric Grand Rounds - UT Health SA 09/14/2018

Pediatric Grand Rounds - UT Health SA 09/14/2018 Fertility Preservation: Who, What, Why, When and How Glenn L. Schattman, MD Associate Professor The Center for Reproductive Medicine and Infertility Weill Medical College of Cornell University Disclosure

More information

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors

The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine

More information

Discussing Fertility Preservation with Breast Cancer Patients

Discussing Fertility Preservation with Breast Cancer Patients Chapter 35 Discussing Fertility Preservation with Breast Cancer Patients Jacqueline S. Jeruss J.S. Jeruss (B) Department of Surgery, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

More information

Brighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director

Brighton & Hove CCG PLS CONFERENCE Dr Carole Gilling-Smith Medical Director Brighton & Hove CCG PLS CONFERENCE 2016 Dr Carole Gilling-Smith Medical Director FERTILITY CHALLENGES IN THE NHS A TERTIARY CARE PERSPECTIVE LEARNING OBJECTIVES Understand the pathways through assisted

More information

BACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive

BACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive BACKGROUNDER Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive Studies find that increased chances of ovulation, menstrual

More information

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.

Fertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr. Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art

More information

Oncofertility: An Emerging Discipline in Obstetrics and Gynecology

Oncofertility: An Emerging Discipline in Obstetrics and Gynecology 23 CME REVIEWARTICLE Volume 68, Number 8 OBSTETRICAL AND GYNECOLOGICAL SURVEY Copyright * 2013 by Lippincott Williams & Wilkins CHIEF EDITOR S NOTE: This article is part of a series of continuing education

More information

T.K. Woodruff et al. (eds.), Oncofertility, Cancer Treatment and Research 156, 55 DOI / _5.

T.K. Woodruff et al. (eds.), Oncofertility, Cancer Treatment and Research 156, 55 DOI / _5. Chapter 5 Clinical Cases in Oncofertility Laxmi A. Kondapalli, Fanzhen Hong, and Clarisa R. Gracia L.A. Kondapalli (B) Department of Reproductive Endocrinology and Infertility, University of Pennsylvania,

More information

Fertility Preservation for Cancer Patients

Fertility Preservation for Cancer Patients Fertility Preservation for Cancer Patients Molly Moravek, MD, MPH Director, Fertility Preservation Program Assistant Professor Reproductive Endocrinology & Infertility Department of Obstetrics & Gynecology

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

BREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG

BREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG BREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG (LHRHa) DURING CHEMOTHERAPY AS A STRATEGY TO REDUCE OVARIAN FAILURE IN EARLY BREAST

More information

Is it the seed or the soil? Arthur Leader, MD, FRCSC

Is it the seed or the soil? Arthur Leader, MD, FRCSC The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,

More information

Web Activity: Simulation Structures of the Female Reproductive System

Web Activity: Simulation Structures of the Female Reproductive System differentiate. The epididymis is a coiled tube found along the outer edge of the testis where the sperm mature. 3. Testosterone is a male sex hormone produced in the interstitial cells of the testes. It

More information

Rejuvenation of Gamete Cells; Past, Present and Future

Rejuvenation of Gamete Cells; Past, Present and Future Rejuvenation of Gamete Cells; Past, Present and Future Denny Sakkas PhD Scientific Director, Boston IVF Waltham, MA, USA Conflict of Interest I have no conflict of interest related to this presentation.

More information

Age and Fertility. A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine

Age and Fertility. A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine 1 Age and Fertility A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine INTRODUCTION Fertility changes with age. Both males and females become fertile in

More information

Laboratory of Pharmacology of Reproductive System The Goldberg Research Institute of Pharmacology, Tomsk, RUSSIA. by Tatyana Borovskaya

Laboratory of Pharmacology of Reproductive System The Goldberg Research Institute of Pharmacology, Tomsk, RUSSIA. by Tatyana Borovskaya Reproductive toxicity of cyto-static drugs and pharmacological ways to reduce it Laboratory of Pharmacology of Reproductive System The Goldberg Research Institute of Pharmacology, Tomsk, RUSSIA by Tatyana

More information

Chapter 9. Yasmin Gosiengfiao, MD

Chapter 9. Yasmin Gosiengfiao, MD Chapter 9 Progress, History and Promise of Ovarian Cryopreservation and Transplantation for Pediatric Cancer Patients T.K. Woodruff and K.A. Snyder (eds.) Oncofertility. Springer 2007 The original publication

More information

A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients

A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients Eric J. Forman, M.D., a Carey K. Anders, M.D., b and Millie A. Behera, M.D.

More information

FERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS

FERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS FERTILITY PRESERVATION OPTIONS FOR CANCER PATIENTS Justo Callejo Olmos, 1 Laura Almeida Toledano 2 1. Professor and Clinical Chief of Gynecology, Department of Obstetrics and Gynaecology, Hospital Sant

More information

NHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs

NHS FUNDED TREATMENT FOR SUBFERTILITY. ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA POLICY GUIDANCE/OPTIONS FOR CCGs CONTENTS Page 1. INTRODUCTION 2 2. GENERAL PRINCIPLES 2 3. DEFINITION OF SUBFERTILITY AND TIMING OF ACCESS TO

More information

Puberty and Fertility. Normal Female Puberty PUBERTY! What about girls with Galactosemia? E Puberty and Fertility Badik Spencer 1

Puberty and Fertility. Normal Female Puberty PUBERTY! What about girls with Galactosemia? E Puberty and Fertility Badik Spencer 1 Puberty and Fertility Jennifer Badik*, MD Pediatric Endocrinology and Jessica Spencer*, MD, MSc Reproductive Endocrinology and Infertility Part One PUBERTY! *no conflicts of interest to report Every girl

More information

Chapter 2 Fertility Management for Women with Cancer

Chapter 2 Fertility Management for Women with Cancer Chapter 2 Fertility Management for Women with Cancer Sanjay K. Agarwal, MD and R. Jeffrey Chang, MD Cancer is now a disease with a variety of treatment options that are leading to longer and more productive

More information

Letter from the Editors

Letter from the Editors October 2015 Volume 3 Issue 2 International Society for Fertility Preservation, 3901 Rainbow Blvd., Kansas City, KS 66160-7316 http://www.isfp -fertility.org/, (913) 588-6201 Letter from the Editors Dear

More information

Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification

Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification Reproductive BioMedicine Online (2010) 21, 566 571 www.sciencedirect.com www.rbmonline.com ARTICLE Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification

More information

Brittany Speller. Copyright by Brittany Speller 2017

Brittany Speller. Copyright by Brittany Speller 2017 Development and Alpha Testing of a Fertility Decision Aid for Young Canadians Diagnosed with Breast Cancer at Risk of Infertility Following Cancer Treatment by Brittany Speller A thesis submitted in conformity

More information

Fertility Preservation in Young Women with Breast Cancer

Fertility Preservation in Young Women with Breast Cancer Curr Obstet Gynecol Rep (2013) 2:59 64 DOI 10.1007/s13669-012-0035-2 MANAGING BREAST PROBLEMS (K AMOS, SECTION EDITOR) Fertility Preservation in Young Women with Breast Cancer Jennifer E. Mersereau Jennifer

More information

Clinical Policy: Fertility Preservation

Clinical Policy: Fertility Preservation Clinical Policy: Reference Number: CP.MP.130 Last Review Date: 09/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information